Endocrine Abstracts

Background: Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance, two major contributors to cardiovascular risk. Even in the absence of detectable insulin resistance, lean, non-diabetic PCOS women demonstrate increased circulating levels of advanced glycated end products (AGEs), known proatherogenic molecules. This adverse cardiovascular risk profile should be considered in the syndrome’s management.Objective: To invest...